19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 3
OA-07-Moving away from isoniazid for TB preventive treatment
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-07-Moving away from isoniazid for TB preventive treatment
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-07-542-21-Safety of high-dose rifamycin for active and latent TB: a systematic review and meta-analysis There is an increasing interest in using rifamycins at higher doses to treat tuberculosis (TB). We performed a systematic review and meta-analysis to examine the safety and efficacy of rifamycin therapy for all patients with TB, by reviewing trials that compared daily administered, high-dose rifamycins to standard-dose rifamycins.

Omri A Arbiv

15:13 - 15:21: OA-07-543-21-Rifampicin maximum, early bactericidal activity not reached at 50 mg/kg The PanACEA HIGHRIF1 trial has recently evaluated the pharmacokinetics (PK) and early bactericidal activity (EBA) of rifampicin at 50 mg/kg. Our analysis focused on defining if earlier developed rifampicin PK and PK-pharmacodynamics models are applicable at a 50 mg/kg dose and if a maximal EBA is reached at 50 mg/kg rifampicin.

Budi O Susanto

15:21 - 15:29: OA-07-544-21-Treatment outcomes of people living with HIV on TB preventive therapy in Lusaka, Zambia Tuberculosis preventive therapy (TPT) has been proven to reduce incidence of TB among people living with HIV (PLHIV). The reduction in TB incidence is more significant in patients who complete a course of TPT compared to those who do not. Improving uptake of TPT among PLHIV is urgently required to reduce the TB burden.

Eugenia Mwamba

15:29 - 15:37: OA-07-545-21-A randomised controlled trial comparing two rifapentine-based short-course regimens for latent TB infection: 1HP vs 3HP 3HP is an attractive regimen for latent tuberculosis infection treatment. However, it is flawed in its systemic drug reactions. By reducing unit drug dosage, 1HP has been shown to have a favourable safety profile in HIV populations. The unanswered questions are the extrapolation of results to non-HIV population and direct comparison with 3HP regimen.

Jann-Yuan Wang

15:37 - 15:45: OA-07-546-21-Preparing for a short-course treatment regimen to prevent TB: catalysing procurement and policy to scale-up 3HP Unitaid funded the IMPAACT4TB project to scale-up 3HP in 12 countries. Work includes updating tuberculosis preventive therapy clinical guidelines, determining the scale of 3HP rollout per country, global 3HP price negotiations, support of generic manufacturers, and discussions with donors and governments to purchase 3HP.

Karin Turner

15:45 - 15:53: OA-07-547-21-Latent TB infection testing and treatment using shortened treatment regimen for contacts and secondary school children in Do Son district, Hai Phong, Viet Nam In 2019, Friends for International TB Relief, together with the Hai Phong TB Programme, implemented a community-wide, mobile screening campaign with integrated tuberculosis (TB) and latent TB infection (LTBI) testing and treatment. We describe the results of the LTBI testing and treatment activities, from screening to treatment completion.

Thuy Thu Thi Dong

15:53 - 16:01: OA-07-548-21-Impact of age on completion rate and systemic drug reaction of rifapentine-based weekly therapy for latent TB infection Under proper medical support and programmatic follow-up, 3HP can be of widespread use among populations of all ages, including the elders. Caution should be given for the high risk of systemic drug reaction in the middle-age population.

Hung-Ling Huang

16:01 - 16:20: Q&A


Loading...
Channel 7
TBS1A-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS1A-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: plenary session
*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.


15:00 - 15:03: Introductory note

Tom H. M. Ottenhoff

15:03 - 15:23: TB biomarkers and first results of the CORTIS trial

Thomas Scriba

15:23 - 15:43: BCG vaccination, trained immunity, TB and COVID-19

Reinout van Crevel

15:43 - 16:03: Antibodies as a bridge between the innate and adaptive immune system

Galit Alter

16:03 - 16:22: Live Q&A


Loading...
Channel 2
OA-06-Different approaches to improve treatment and care
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-06-Different approaches to improve treatment and care
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-06-536-21-Community health workers augment the cascade of TB detection to care in urban slums of two metro cities in India The Tuberculosis Health Action Learning Initiative (THALI) recruited community health workers, in urban slums in two metro cities in India, to augment tuberculosis (TB) detection to care cascade. Their performance and TB treatment outcomes improve over time. It will be important to examine the cost per-TB case detected and successfully treated.

RAJARAM Potty

15:13 - 15:21: OA-06-537-21-Improving isoniazid preventive therapy coverage among children aged 0-14 years living with HIV through designating special clinic days: case of Kapelebyong Health Centre IV Isoniazid preventive therapy demonstrated efficacy of over 60% in preventing active tuberculosis (TB) among people with latent TB infection. However, uptake is low. People of all ages living with HIV, who attend the clinic at the same time, limits opportunities for special care, emphasising the need for age-sensitive HIV clinics to address unique challenges. 

Pius Ongareno

15:21 - 15:29: OA-06-538-21-Using market-based e-pharmacies for delivering free TB drugs to patients treated in the private sector: lessons learned from a pilot in Madhya Pradesh, India This innovative demonstration model of engaging e-pharmacy companies for door step delivery of national TB elimination programme-supplied anti-TB drugs, diagnostic services and treatment adherence support, to patients treated in the private sector.

Varsha Rai

15:29 - 15:37: OA-06-539-21-The potential of mHealth to improve TB awareness and case detection in Tanzania Provide support to the Tanzania National Tuberculosis and Leprosy Program (NTLP)  through the implementation of mHealth technologies to increase case detection and enhance TB knowledge among the general public in Tanzania.

Eunice Moturi

15:37 - 15:45: OA-06-540-21-Identifying subpopulations at high-risk for severe adherence challenges in the treatment of multi- and extensively drug-resistant TB and HIV In generalised epidemics of drug-resistant tuberculosis (DR-TB) and HIV, identifying high-risk subpopulations is critically important to improve treatment outcomes and prevent amplification of resistance. We hypothesised that an electronic dose-monitoring device could empirically identify adherence-challenged patients and that a mixed methods approach would characterise treatment challenges.

Jennifer Zelnick

15:45 - 16:20: Q&A


Loading...
Community Connect
Activating a Human Rights Based Tuberculosis Response
event_note
Loading...
query_builder 15:00 - 16:30 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Community Connect
mic English
Activating a Human Rights Based Tuberculosis Response
This session takes place on Zoom.us

Panel session: This session will be a follow up to the Human Rights based Response to TB Workshop conducted last year during the Union conference. The session will include presentation and discussion on how to bring a change at the policy level in adopting the HR policy and guidelines at country level. This will be followed by Q and A.

1. Moderator - Blessina Kumar, CEO, Global Coalition of TB Activists
2. Prof. Brian Citro, Assistant Professor, Northwestern Pritzker School of Law
3. Allan Maleche, ED, KELIN
4. Priyam Cherian, Legal Officer, Lawyers Collective
5. Nyokabi Njogu, Advocate, High Court of Kenya
6. Jeffry Acaba, Community representative, APCASO
7. Ani Hernasari, Community representative, POP TB Indonesia
Loading...
Channel 1
SS1-Sars-CoV2 - the hope for a vaccine
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Special session
mic English
SS1-Sars-CoV2 - the hope for a vaccine
*Please scroll down for more information*
Since the SARS-CoV-2 virus was identified in December 2019, over 37 million people have been infected, and over 1 million deaths have been reported worldwide. Our hopes have been largely focused on the development of a preventative vaccine. But data suggests that immunity may be short lived following infection raises many questions and possible challenges for vaccine development.

15:00 - 15:05: Session introduction


15:05 - 15:20: COVID19 - Public health and scientific challenges

Anthony Fauci

15:20 - 15:30: The COVID19 vaccine portfolio

Vasee Moorthy

15:30 - 15:40: How do we ensure equitable global access to COVID-19 vaccines?

Suerie Moon

15:40 - 15:50: Vaccine hesitancy: until we understand public opinion, we cannot hope to change it

Jeffrey Lazarus

15:50 - 16:00: Going from efficacy trials to public health intervention

Kate O'Brien

16:00 - 16:25: Live Q&A and moderated discussion

Vasee Moorthy
Kate O'Brien
Suerie Moon
Jeffrey Lazarus

Loading...
Channel 6
SP-09-Ending TB in vulnerable populations through operational research, capacity building and evidence-informed decision making in Eastern Europe and Central Asia (Find-Treat-All).
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-09-Ending TB in vulnerable populations through operational research, capacity building and evidence-informed decision making in Eastern Europe and Central Asia (Find-Treat-All).
*Please scroll down for more information*
The objective is to present new evidence on optimised case finding, use of digital technology for TB diagnosis and care, and adjunctive interventions in complex cases for key populations in Eastern Europe and Central Asia (EECA). The evidence was generated from EECA researchers under the Structured Operational Research and Training Initiative (SORT IT), which is a global partnership coordinated by the TDR, The Special Programme for Research and Training in Tropical Diseases. The specific SORT IT programme that led to this symposium was implemented by Tuberculosis Research and Prevention Center, Armenia, the Alliance for Public Health, Ukraine, The Union and TDR.

15:00 - 15:05: Introduction

15:05 - 15:15: Breaking the one size fits all paradigm: introduction of optimised case finding of TB among key populations in UkraineMissed tuberculosis (TB) cases are disproportionally concentrated among vulnerable populations that often cannot access health systems. These include socially marginalised individuals (people who inject drugs, displaced, homeless, Roma and former prisoners). Based on experience from an optimised case finding (OCF) strategy, which has been effective in HIV detection among key populations, the Alliance for Public Health in Ukraine has adapted a similar strategy for active TB case finding among vulnerable groups. The OCF strategy empowers index TB cases to refer up to eight close contacts within their social network for TB investigations, in contrast to the usual contact tracing strategy limited to household contacts. Study sites were TB clinics in four regions of Ukraine. Four thousand eight hundred contacts of 600 index TB patients, registered between July 2018 and March 2020, were assessed with respect to numbers of TB contacts referred for investigations, the numbers diagnosed and treated for TB, and the numbers needed to screen.
Liliia Masyuk
Olga Denisiuk

15:15 - 15:25: Scale-up and impact of an electronic medical record system (Open MRS) and GxAlert on diagnosis of TB and linkage to treatment in TajikistanThe advent of the automated Xpert MTB/RIF assay has so far failed to speed up time between diagnosis and treatment of tuberculosis (TB), mainly because of the need for personnel and paper-based interfaces to link results with TB registers. GxAlert is an electronic data monitoring system that automatically connects Xpert instruments to the network and mobile channels to communicate assay results. This should lead to patients being diagnosed and initiated on treatment more quickly. Tajikistan started scaling up GeneXpert instruments in 2014. From 2017 these instruments were connected to GxAlert. During this period, the country scaled-up a new Open MRS medical information system allowing more reliable recording and reporting of TB control efforts. This study presents the scale-up and national coverage of GeneXpert / GxAlert and Open MRS in Tajikistan, between 2014 and 2019, and the impact of this on TB diagnosis and timely linkages between diagnosis and treatment.
Shodmon Khushvakhtov

15:25 - 15:35: Outcomes of video observed TB treatment for drug-susceptible TB in the Republic of MoldovaAsynchronous video observed treatment (aVOT) has been proposed as an alternative method of ensuring medication adherence in tuberculosis (TB) patients, compared with directly observed therapy (DOT). The current study used 2016-2017 secondary data from the randomised clinical trial (RCT) piloted aVOT strategy, in Chisinau, and data from the national TB register. From 647 TB patients included in the study, 169 were from the RCT group (83 – in aVOT and 86 – in DOT) and 478 – DOT in practical conditions (control group). Based on the suggestions of the parent study aVOT may be an acceptable approach to treatment monitoring. Our supplementary results show that aVOT was superior to DOT in terms of treatment outcomes as well; aVOT was associated with short- and long-term TB treatment favourable outcomes. aVOT, as a new patient-centred approach improving treatment adherence and outcomes, might be recommended as an alternative to DOT strategy in the Republic of Moldova.
Svetlana Doltu

15:35 - 15:45: People who inject drugs in Ukraine: comparative analysis of TB treatment outcomes in relation to opioid substitution therapyPeople who use injectable drugs (PWID), who are often socially marginalised and have limited access to health services, are at high risk of being infected with Mycobacterium tuberculosis and developing tuberculosis (TB). Many PWID are also infected with HIV and hepatitis C. Opioid substitution therapy (OST – using methadone or buprenorphine) is one of the pillars of harm reduction strategies for PWID and should be an integral part of TB care. In Ukraine, the Alliance for Public Health coordinates TB and HIV prevention and care services for PWID and has integrated a model of 'OST with TB care at the same facility'. Between July 2017 and July 2019, there were 200 PWID diagnosed with TB in five large regions of Ukraine. The current study documented numbers on OST, socio-demographic and clinical characteristics of those on and off OST and treatment outcomes in relation to OST, HIV status and hepatitis C.
Tetiana Fomenko

15:45 - 15:55: The effect of psychotherapy/psychiatric support for alcohol use disorder for multidrug-resistant TB in Zhytomyr, UkraineUkraine is among the high burden countries for multidrug/rifampicin-resistant tuberculosis (MDR-TB/RR-TB). The country ranks in the top ten for years lost due to disability and premature mortality as a result of alcohol abuse, and TB control efforts are often adversely affected by alcohol use disorder (AUD). Mental health interventions can be effective in reducing alcohol use and together with psychosocial support, these may improve patients’ adherence to TB treatment and result in more favorable TB treatment outcomes. Of 73 patients with RR-TB in Zhytomyr region, Ukraine, 33 were screened positive for AUD and eligible for mental health interventions: 22 received this support and 11 declined. This study compared the two groups with respect to socio-demographic and clinical characteristics, measures of depression, adherence to TB medications and interim/final TB treatment outcomes. The study also assessed why some patients declined to be helped.
Vitalii Plokhykh

15:55 - 16:20: Q&A session

Loading...
Channel 4
SP-12-Scale-up of joint action on diabetes and TB: lessons from the field
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-12-Scale-up of joint action on diabetes and TB: lessons from the field
*Please scroll down for more information*
Addressing comorbidities is a core component of patient-centred care within the End TB Strategy. Diabetes is associated with a two to three-fold risk of TB. TB can temporarily cause impaired glucose tolerance and a person with TB is significantly more at risk of dying or relapsing if they also have diabetes - all important reasons for collaborative action as outlined in The Union and World Health Organization 2011 Collaborative Framework for Care and Control of TB and Diabetes. This symposium will present evidence on the global uptake of collaborative action on TB and diabetes and share barriers, enablers, plans and opportunities for scale-up.

16:30 - 16:35: Introduction

16:35 - 16:45: Global status on uptake of the Union/World Health Organization Collaborative Framework for the Management of Tuberculosis and DiabetesThe Union/World Health Organization (WHO) Collaborative Framework for the Management of Tuberculosis and Diabetes was published in 2011. While we have seen impressive scale-up of collaborative action on HIV-associated tuberculosis (TB) globally during this period, uptake and scale-up of collaborative TB and diabetes activities appears to have been limited and difficult to gauge. This presentation will introduce the symposium and provide an overview of findings from a policy review conducted by WHO to assess uptake by high burden TB countries of the collaborative framework for the management of tuberculosis and diabetes and outline plans to promote further scale-up.
Annabel Baddeley

16:45 - 16:55: Addressing comorbidities as part of high impact TB interventions in Global Fund funding requests and grantsThe presentation will share opportunities from the Global Fund to address comorbidity as one of the high impact interventions – this includes the Global Fund strategy and policy on supporting comorbidity, integrated services and promotion of innovations. Further opportunities are available through catalytic funding to support innovative interventions to find missing people with tuberculosis/drug-resistant tuberculosis (TB), including among high risk groups such as people with diabetes. Additional resources to address TB and comorbidity could be leveraged through existing country grants (savings and reprogramming), portfolio optimisation and new grants.
Mohammed Yassin

16:55 - 17:05: Challenges, enablers and plans for scaling up integrated action on TB and diabetes: lessons from PakistanThe dual burden of diabetes and tuberculosis (TB) is a serious and growing challenge for the poorly resourced health system of Pakistan, which ranks 5th among the high TB burden countries. The number of diabetics are estimated to rise to 13.9 million by 2020 in Pakistan, increasing country ranking to 4th in the world. This presentation will give an overview of studies that have been conducted to pilot bi-directional screening for diabetes in TB clinics and for TB in diabetes clinics. It will also discuss the challenges and barriers to integration at all levels of the health system and how the country plans to ensure integrated and structured bi-directional screening, referral, case management and follow-up is scaled up from 2020-2023.
Aurangzaib Quadir Baloch

17:05 - 17:15: Experience of initiating TB preventive treatment among people with diabetes in BrazilThe national tuberculosis (TB) programme of Brazil has recently been introducing a policy on TB prevention among people with diabetes. This presentation will give an overview of the epidemiology of TB and diabetes in Brazil, common aspects and areas for synergy between the two programmes, Brazil’s experience of introducing programmatic management of latent TB infection as well as preliminary results of TB preventive treatment in people affected by diabetes.
Denise Arakaki-Sanchez

17:15 - 17:25: Introducing diabetes into TB-HIV collaboration: opportunities and plans for addressing multimorbidity in ZimbabweZimbabwe is one of the high tuberculosis (TB) burden countries with more than half of people with TB co-infected with HIV. In 2017, the prevalence of diabetes among adults in Zimbabwe is estimated to be 1.8% and over 75.0% of those with diabetes had never been diagnosed. This presentation will give an overview of the epidemiological background and the steps taken to assess feasibility of implementation and to scale-up collaborative action on TB and diabetes in Zimbabwe.  It will further discuss the challenges, enablers, opportunities and plans for national scale-up of integrated TB, diabetes and HIV care.
Charles Sandy

17:25 - 17:50: Q&A session

Loading...
Channel 5
SP-13-Deadly partners - COVID-19, non-communicable diseases and tobacco
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-13-Deadly partners - COVID-19, non-communicable diseases and tobacco
*Please scroll down for more information*
There has been a great deal of discussion about the potential relationship between COVID-19 and tobacco use. The underlying logic of a smoking-COVID-19 relationship is that smoking is an established risk factor for respiratory infections because it undermines the immunological response that a person can otherwise mount against a viral infection. Furthermore, there is a very strong relationship between smoking and non-communicable diseases that has emerged as a risk factor for COVID-19 severity and death. Studies from China show that the odds of progression towards serious illness are 14 times higher among people with a history of smoking.

16:30 - 16:35: Introduction

16:35 - 16:47: COVID-19, non-communicable diseases and impact on young peopleYoung people, especially those living with non-communicable diseases (NCDs) and its associated risk factors are vulnerable and susceptible to developing COVID-19 and its complications. This includes incomplete treatment regimens and restricted access to public health services for chronic conditions in times of lockdown and social distancing. Not to forget the major impact on mental health of young people. On the other hand, young people are also critical in promoting preventive messages for risk mitigation, disseminating information to their families, peer groups and community during this global crisis. Therefore, meaningful involvement of young people during the time of pandemic, as well as prevention of NCDs, is significant to the preparedness efforts, for not only the current, but also future public health crises.
Ishu Kataria

16:47 - 16:59: COVID-19 and lung healthCurrently evidence is lacking on how underlying lung disease will affect the severity and outcomes of COVID-19.  The longer term impact of COVID-19 on lung health is unknown but with large numbers of people requiring high flow oxygen and/or ventilation there are concerns regarding residual lung damage in COVID-19 survivors. The data on these areas will be reviewed as well as discussing what services need to be planned for COVID-19 survivors.
Grania Brigden

16:59 - 17:11: Deadly partners: COVID-19 and tobaccoTobacco smoking appears to be an important and entirely avoidable risk factor for a poorer prognosis in COVID-19. COVID-19 has not only severely constrained health systems, but also could have a cascading impact on the progress that countries were making towards different goals and targets of the United Nations Sustainable Development Goals (SDGs). With the looming danger of economic recession, it becomes even more vital to avert the huge financial cost of tobacco use to the global economy. The urgency to prioritise stronger action on comprehensive tobacco control is mandatory for optimal response to contain the COVID-19 pandemic.
Tara Singh Bam

17:11 - 17:23: Responding COVID-19 and non-communicable disease risk factorsTobacco causes eight million deaths every year and is a known risk factor for severe disease and death from many respiratory infections. Emerging evidence has suggested that smoking increases the risk of severe COVID-19 outcomes as well as the risk of death from COVID-19. However, in the absence of robust population studies to date, the association between smoking and infection with SARS CoV2 and between smoking and hospitalisation has not been reliably quantified.  This presentation will review the evidence on smoking and COVID-19 and will position the findings within the context of the wider literature and body of evidence. It will also look at risk communication of the findings on tobacco use and COVID-19 in the overall context of harms from tobacco use that are well established.
Hebe Gouda

17:23 - 17:50: Q&A session

Loading...
Channel 1
OA-09-What person-centred care really means
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-09-What person-centred care really means
*Please scroll down for more information*


16:30 - 16:35: Introduction


16:35 - 16:43: OA-09-550-21-Using the patient pathway analysis method to align care-seeking and service delivery in development of a person-centred, national strategic plan The patient pathway analysis uses data to identify a mismatch between tuberculosis (TB) healthcare-seeking and service delivery. Fifty eight percent of the population initially sought care in private facilities, of which only 2% were equipped with diagnostic capacity for TB, emphasising the need to engage private sector facilities in TB control.

Moses Arinaitwe

16:43 - 16:51: OA-09-551-21-A 360 degree view of TB-related stigma in Uganda: findings from a mixed methods study involving perceptions from patients, providers and communities Stigma is a key driver that hinders tuberculosis (TB) control programmes by negatively affecting delay in care-seeking and treatment adherence. A mixed methods assessment was conducted to understand perceptions and knowledge of TB-related stigma among TB providers, patients and community members, to inform  TB programme strengthening efforts in Uganda.

Nikki Davis

16:51 - 16:59: OA-09-552-21-Support for integrating TB preventive treatment into community antiretroviral refill groups among people on antiretroviral treatment in Zimbabwe Zimbabwe's 2018 tuberculosis (TB) incidence - 210/100,000 - is among the highest globally. However, only 11% of people living with HIV (PLHIV) and newly enrolled in care, were on TB preventive treatment (TPT) in 2017. Community antiretroviral refill groups can be an efficient way to scale-up TPT in PLHIV in Zimbabwe. 

Jennifer M. Zech

16:59 - 17:07: OA-09-553-21-Integrating mental health services into TB care: Gujarat, India Mental health interventions to treat depression among tuberculosis (TB) patients were integrated into routine TB workflows. Healthcare workers, trained in psychotherapeutic counselling, screened for depression symptoms, administered 4-6 sessions with patients and measured reduction in depression symptoms with each session.

Sirisha Papineni

17:07 - 17:15: OA-09-554-21-Journey patterns and models of care observed in patients receiving drug-resistant TB treatment in South Africa This analysis uses spatio-temporal mapping of patient care journeys in South Africa to describe diverse patterns - ranging from highly centralised to highly decentralised - and uses these to provide structure to illustrate existing models of care. Five dominant geospatial movement patterns of patient journeys, and the associated care models, are described. 

Lindy Dickson-Hall

17:15 - 17:23: OA-09-555-21-Implementation of a supportive care package to strengthen drug-resistant TB patients' adherence to treatment in Xi'an, China Implementation of a comprehensive, supportive care package to strengthen treatment enrollment, retention and treatment adherence to among drug-resistant tuberculosis patients managed by Xi’an City Chest Hospital, western China

Ali Zhao

17:23 - 17:50: Q&A


Loading...
Channel 7
TBS1B-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS1B-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: oral abstract presentations
*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-01-Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis

Valerie A.C.M. Koeken

16:40 - 16:48: TBS-OA-02-Vaccination with intravenous BCG protects SIV+ macaques from tuberculosis.

Erica Larson

16:48 - 16:56: TBS-OA-03-A pilot study on plasma metabolomic characterization of patents with MDR-TB

Qi Tan

16:56 - 17:04: TBS-OA-04-A 22-gene transcriptomic model predicting individual therapy durations in multidrug-resistant tuberculosis

Jan Heyckendorf

17:04 - 17:12: Live Q&A


Loading...
Processing. Please wait.
Loading...